InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.096 0.001 (1.03%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$40 Cleansing Notice 13 Jul 2026 5:05PM $0.098 $0.096 fallen by 2.04%
$40 Application for quotation of securities - IMU 13 Jul 2026 4:58PM $0.098 $0.096 fallen by 2.04%
$40 Application for quotation of securities - IMU 9 Jul 2026 4:23PM $0.105 $0.096 fallen by 8.57%
$40 Notification of cessation of securities - IMU 7 Jul 2026 7:27PM $0.105 $0.096 fallen by 8.57%
$40 Change of Director's Interest Notice x5 7 Jul 2026 4:58PM $0.105 $0.096 fallen by 8.57%
$40 Imugene Capital Raising Presentation 7 Jul 2026 10:02AM $0.135 $0.096 fallen by 28.89%
$40 Proposed issue of securities - IMU 7 Jul 2026 9:49AM $0.135 $0.096 fallen by 28.89%
$40 $11.1 Million Placement Completed to Advance azer-cel 7 Jul 2026 9:49AM $0.135 $0.096 fallen by 28.89%
$40 Initial Director's Interest Notice - CG & MK 6 Jul 2026 1:45PM $0.135 $0.096 fallen by 28.89%
$40 Trading Halt 3 Jul 2026 9:31AM $0.135 $0.096 fallen by 28.89%
$40 New Complete Response in the Concurrent BTKi azer-cel Cohort 1 Jul 2026 10:00AM $0.113 $0.096 fallen by 14.67%
$40 First Complete Response in Concurrent BTKi azer-cel Cohort 30 Jun 2026 11:45AM $0.100 $0.096 fallen by 4%
$40 Azer-cel Granted FDA Fast Track Designation for CLL and MZL 9 Jun 2026 10:50AM $0.091 $0.096 risen by 6.08%
$40 Notification regarding unquoted securities - IMU 2 Jun 2026 5:57PM $0.105 $0.096 fallen by 8.57%
$40 azer-cel CAR-T naive data presented at ASCO Annual Meeting 1 Jun 2026 8:33AM $0.115 $0.096 fallen by 16.52%
$40 First Patient in BTKi Combination Cohort of azer-cel study 28 May 2026 9:41AM $0.110 $0.096 fallen by 12.73%
$40 Appointment of 2 non-Executive Directors 26 May 2026 9:47AM $0.110 $0.096 fallen by 12.73%
$40 Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract 22 May 2026 9:27AM $0.096 $0.096 fallen by 0%
$40 Change of Director's Interest Notice - PH 18 May 2026 4:11PM $0.091 $0.096 risen by 5.49%
$40 Change of Director's Interest Notice - LC 15 May 2026 3:34PM $0.098 $0.096 fallen by 2.04%
$40 Ceasing to be a substantial holder 12 May 2026 8:26AM $0.110 $0.096 fallen by 12.73%
$40 Application for quotation of securities - IMU 5 May 2026 8:33AM $0.105 $0.096 fallen by 8.57%
$40 Notice under section 708A(12C)(e) of the Corporations Act 1 May 2026 6:19PM $0.110 $0.096 fallen by 12.73%
$40 Notification regarding unquoted securities - IMU 1 May 2026 6:05PM $0.110 $0.096 fallen by 12.73%
$40 Notification of cessation of securities - IMU 1 May 2026 5:58PM $0.110 $0.096 fallen by 12.73%

1 - 25 of 1177 results

Page 1 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.